tiprankstipranks
Photocure ASA (PHCUF)
OTHER OTC:PHCUF

Photocure ASA (PHCUF) Stock Price & Analysis

8 Followers

PHCUF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.97 - $7.34
Previous Close$4.99
Volume100.00
Average Volume (3M)1.40K
Market Cap
$137.97M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-2772.2
Beta0.29
May 15, 2024
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume1,400
Standard Deviation0.16
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.60%0.10%99.30%
0.00%
Insiders
0.10% Other Institutional Investors
99.30% Public Companies and
Individual Investors

PHCUF FAQ

What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was $3.97 and its highest was $7.34 in the past 12 months.
    What is Photocure ASA’s market cap?
    Currently, no data Available
    When is Photocure ASA’s upcoming earnings report date?
    Photocure ASA’s upcoming earnings report date is May 15, 2024 which is in 4 days.
      How were Photocure ASA’s earnings last quarter?
      Photocure ASA released its earnings results on Feb 21, 2024. The company reported $0.037 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.048.
        Is Photocure ASA overvalued?
        According to Wall Street analysts Photocure ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Photocure ASA pay dividends?
          Photocure ASA pays a Notavailable dividend of $0.18 which represents an annual dividend yield of N/A. See more information on Photocure ASA dividends here
            What is Photocure ASA’s EPS estimate?
            Photocure ASA’s EPS estimate is -$0.02.
              How many shares outstanding does Photocure ASA have?
              Photocure ASA has 27,120,820 shares outstanding.
                What happened to Photocure ASA’s price movement after its last earnings report?
                Photocure ASA reported an EPS of $0.037 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -6.981%.
                  Which hedge fund is a major shareholder of Photocure ASA?
                  Currently, no hedge funds are holding shares in PHCUF
                  ---

                  Photocure ASA Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -8.43%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -0.10%
                  Trailing 12-Months
                  Asset Growth
                  -4.05%
                  Trailing 12-Months

                  Company Description

                  Photocure ASA

                  PhotoCure ASA is a Norway based specialty pharmaceutical company. Its technology platform is focused on the field of photodynamic diagnosis and treatment in the areas of dermatology and cancer. The group has operations in Norway, Sweden, Denmark, Finland and the United States. The operating segments of the group are Commercial franchise and Development portfolio. The company markets product through its commercial operation in the Nordic region under the brand name Hexvix and in the US under the brand name Cysview. It generates prime revenue from the Commercial franchise segment which includes the Hexvix and Cysview products. In addition, the firm also has two device products, Cevira and Visonac, both targeted at indications with medical need and market potential.
                  ---

                  PHCUF Company Deck

                  ---

                  PHCUF Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  PHCUF Stock 12 Month Forecast

                  Average Price Target

                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"May<br/>2023","9":"Aug<br/>2023","12":"Nov<br/>2023","25":"Nov<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.23,4.827692307692308,4.4253846153846155,4.023076923076923,3.620769230769231,3.2184615384615385,2.8161538461538465,2.413846153846154,2.0115384615384615,1.609230769230769,1.2069230769230765,0.8046153846153841,0.4023076923076925,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.23,4.827692307692308,4.4253846153846155,4.023076923076923,3.620769230769231,3.2184615384615385,2.8161538461538465,2.413846153846154,2.0115384615384615,1.609230769230769,1.2069230769230765,0.8046153846153841,0.4023076923076925,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.23,4.827692307692308,4.4253846153846155,4.023076923076923,3.620769230769231,3.2184615384615385,2.8161538461538465,2.413846153846154,2.0115384615384615,1.609230769230769,1.2069230769230765,0.8046153846153841,0.4023076923076925,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.13,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.78,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.85,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.9,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.77,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.97,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.91,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.56,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  BioLife Solutions
                  Aptose Biosciences
                  Avid Bioservices
                  Fate Therapeutics

                  Best Analysts Covering PHCUF

                  1 Year
                  1 Year Success Rate
                  2/2 ratings generated profit
                  100%
                  1 Year Average Return
                  +4.45%
                  reiterated a buy rating 9 months ago
                  Copying Ole Andreas Krohn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +4.45% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis